Kenichi Shimada

Kenichi Shimada

Auto-generated profile, based on publicly available information

Kenichi Shimada

Brigham and Women’s Hospital, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Cell
Verified
Journal Article
Closed access
WYWan Seok Yang
Wan Seok Yang
RSRohitha SriRamaratnam
Rohitha SriRamaratnam
MWMatthew E. Welsch
Matthew E. Welsch
KSKenichi Shimada
Kenichi Shimada
Rachid SkoutaRachid Skouta
Rachid Skouta
BSBrent R. Stockwell
Brent R. Stockwell

5 July 2017 in Nature
Verified
Journal Article
Closed access
PDF file
VVVasanthi S. Viswanathan
Vasanthi S. Viswanathan
MRMatthew J. Ryan
Matthew J. Ryan
HDHarshil D. Dhruv
Harshil D. Dhruv
SGShubhroz Gill
Shubhroz Gill
OEOssia M. Eichhoff
Ossia M. Eichhoff
SSStuart L. Schreiber
Stuart L. Schreiber

4 March 2014 in Journal of the American Chemical Society
Verified
Journal Article
Open access
Rachid SkoutaRachid Skouta
Rachid Skouta
SDScott J. Dixon
Scott J. Dixon
JWJianlin Wang
Jianlin Wang
DDDenise E. Dunn
Denise E. Dunn
MOMarina Orman
Marina Orman
BSBrent R. Stockwell
Brent R. Stockwell
Ferrostatin-1 (Fer-1) inhibits ferroptosis, a form of regulated, oxidative, nonapoptotic cell death. We found that Fer-1 inhibited cell death in cellular models of Huntington’s disease (HD), periventricular leukomalacia (PVL), and kidney dysfunction; Fer-1 inhibited lipid peroxidation, but not mitochondrial reactive oxygen species formation or lysosomal membrane permeability. We developed a mechanistic model to explain the activity of Fer-1, which guided the development of ferrostatins with improved properties. These studies suggest numerous therapeutic uses for ferrostatins, and that lipid peroxidation mediates diverse disease phenotypes.

9 May 2016 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
KSKenichi Shimada
Kenichi Shimada
Rachid SkoutaRachid Skouta
Rachid Skouta
AKAnna Kaplan
Anna Kaplan
WYWan Seok Yang
Wan Seok Yang
MHMiki Hayano
Miki Hayano
BSBrent R Stockwell
Brent R Stockwell
Modulatory profiling of lethal small-molecule compounds identified FIN56 as an inducer of ferroptosis. FIN56 promotes the degradation of glutathione peroxidase 4 and directly activates squalene synthase, an enzyme involved in cholesterol synthesis. Apoptosis is one type of programmed cell death. Increasingly, non-apoptotic cell death is recognized as being genetically controlled, or 'regulated'. However, the full extent and diversity of alternative cell death mechanisms remain uncharted. Here we surveyed the landscape of pharmacologically accessible cell death mechanisms. In an examination of 56 caspase-independent lethal compounds, modulatory profiling showed that 10 compounds induced three different types of regulated non-apoptotic cell death. Optimization of one of those ten resulted in the discovery of FIN56, a specific inducer of ferroptosis. Ferroptosis has been found to occur when the lipid-repair enzyme GPX4 is inhibited. FIN56 promoted degradation of GPX4. FIN56 also bound to and activated squalene synthase, an enzyme involved in isoprenoid biosynthesis, independent of GPX4 degradation. These discoveries show that dysregulation of lipid metabolism is associated with ferroptosis. This systematic approach is a means to discover and characterize novel cell death phenotypes.

1 February 2016 in Cell Chemical Biology
Verified
Journal Article
Closed access
KSKenichi Shimada
Kenichi Shimada
MHMiki Hayano
Miki Hayano
NPNen C. Pagano
Nen C. Pagano
BSBrent R. Stockwell
Brent R. Stockwell

1 February 2012 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MWMichel Weïwer
Michel Weïwer
JBJoshua A. Bittker
Joshua A. Bittker
TLTimothy A. Lewis
Timothy A. Lewis
KSKenichi Shimada
Kenichi Shimada
WYWan Seok Yang
Wan Seok Yang
BMBenito Munoz
Benito Munoz